Interventional Therapies for Resistant Hypertension: A Brief Update

Area of Science:

• Cardiology
• Nephrology
• Interventional Cardiology

Background:

• Resistant hypertension presents a significant clinical challenge with limited therapeutic options.
• Catheter-based renal artery denervation (RDN) emerged as a potential treatment, showing early promise in feasibility studies.
• The SYMPLICITY 3 trial in 2014 yielded disappointing results, failing to show a significant blood pressure reduction compared to a sham procedure.

Purpose of the Study:

• To evaluate the efficacy of renal artery denervation (RDN) for managing resistant hypertension.
• To discuss the impact of the SYMPLICITY 3 trial on the perception and future of RDN.
• To explore alternative interventional strategies for resistant hypertension.

Main Methods:

• Review of early feasibility trials and the pivotal SYMPLICITY 3 trial for renal artery denervation.
• Analysis of factors contributing to the trial's outcome.
• Consideration of emerging interventional targets and patient selection criteria.

Main Results:

• Early RDN trials demonstrated significant and sustained blood pressure reductions.
• The SYMPLICITY 3 trial did not achieve statistical significance in blood pressure reduction between RDN and control groups.
• Disappointment in RDN efficacy led to a re-evaluation of its role in resistant hypertension management.

Conclusions:

• Despite initial setbacks, the potential for interventional therapies in resistant hypertension remains.
• Improved understanding of the procedure, technological advancements, and identification of specific patient subgroups are crucial.
• Alternative targets like baroreceptor activation therapy and arteriovenous shunts offer new avenues for managing resistant hypertension.